Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Tracking Mason Hawkins' Southeastern Asset Management Portfolio - Q4 2017 Update

11h seekingalpha
Mason Hawkins’ 13F portfolio value decreased from $8.32B to $8.08B this quarter. The number of positions increased from 27 to 30. (327-0)

Patent Office Puts Allergan's Mohawk Deal Out Of Its Misery

2018-02-24 seekingalpha
PTAB ruled the St. Regis Mohawk Tribe could not claim sovereign immunity to thwart an IPR for Restasis patents. (68-0)

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2017 Update

2018-02-24 seekingalpha
Glenview Capital Management's 13F portfolio value increased from $17.23B to $18.50B this quarter. The number of positions increased from 56 to 58. (853-1)

Will Analysts Abandon Allergan On Esmya Headwinds?

2018-02-23 seekingalpha
The European Medicines Agency advised that no new patients take Esmya due to potential links to liver injury. (68-0)

Top Analyst Upgrades and Downgrades: Albermarle, Allergan, Boston Scientific, eBay, FedEx, Gogo, LendingTree, Nokia, UPS, Vertex and More

2018-02-23 247wallst
The stock market has demonstrated that perhaps the return of volatility is real after Wednesday’s big gains suddenly turned into a big loss in the final 30 minutes of trading. Now stocks are indicated just marginally higher after digesting more of the verbiage from the Federal Open Market Committee minutes yesterday. With the bull market approaching nine years old, the trend that has worked without fail for roughly six years has been to buy the dips every time. (177-1)

Amgen: Outlook

2018-02-23 seekingalpha
Amgen (AMGN) is one of the major biotechnology and pharmaceutical companies. Revenue in 2017 was $22.85 billion. Non-GAAP net income in 2017 was $9.25 billion and non-GAAP EPS was $12.58. (264-0)

Abbvie's Uterine Fibrosis Candidate Meets Goal in Study

2018-02-23 zacks
AbbVie Inc. ((ABBV - Free Report) ) along with partner Neurocrine Biosciences, announced that the phase III study oftheir late stage candidateelagolix met its primary endpoint in women with uterine fibroids. Top-line results from the first of the two pivotal phase III studies on elagolix (ELARIS UF-I) revealed that at six month, elagolix, in combination with low-dose add-back hormone therapy, reduced heavy menstrual bleeding compared to placebo. (164-0)

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q4 2017 Update

2018-02-22 seekingalpha
Wallace Weitz's 13F portfolio value decreased marginally from $2.43B to $2.40B. The number of positions decreased from 79 to 77. (668-1)

Another Phase III Win For Neurocrine Biosciences

2018-02-22 seekingalpha
AbbVie announced that elagolix met its primary and secondary efficacy endpoints in the first of two Phase III studies for uterine fibroids. (163-1)

Middlemen Play Gatekeeper in Battle to Curb Soaring Drug Costs - Bloomberg

2018-02-22 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (347-1)

Tracking David Tepper's Appaloosa Management Portfolio - Q4 2017 Update

2018-02-21 seekingalpha
Appaloosa increased Micron Technology, Facebook, Powershares QQQ ETF, & Apple while reducing Alphabet, Energy Transfer Partners LP, and Williams Partners LP. (1473-13)

Teva's Problems Continue to Mount With No Relief in Sight

2018-02-21 zacks
Israel-based drugmaker, Teva Pharmaceutical Industries Limited (TEVA - Free Report) is in a major mess right now. The question now is how will the world’s largest generic maker recover? (266-1)

Neurocrine Biosciences Shows Again That Sometimes The Tortoise Wins

2018-02-20 seekingalpha
Neurocrine's deliberate approach to pipeline development could lead to four drugs and six indications commercialized over the next four to five years, with multiple $1 billion-plus opportunities. (149-0)

Fogo de Chao shares halted for news

2018-02-20 marketwatch
Brazilian steak house chain Fogo de Chão Inc. said Tuesday it has reached an agreement to be acquired by private-equity firm Rhone Capital units in an all-cash deal valued at $560 million. Under terms of the deal, Fogo de Chão shareholders will receive $15.75 a share in cash, equal to a 25.5% premium over its closing share price on Friday. The deal is expected to close in the second quarter. The news comes after the company's board conducted a review of its strategic options; the company went public in 2015. (113-0)

Tracking John Paulson's Paulson & Company Portfolio - Q4 2017 Update

2018-02-20 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s US stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 02/14/2018. Please visit our Tracking John Paulson’s Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q3 2017. (1077-8)


CUSIP: G0177J108